International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant news
Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.
Dermavant Sciences, a subsidiary of Roivant Sciences
Categories
Recent Posts
Almirall Press Release Graphic

Happify Health and Almirall Partner Together to Launch Claro

022 SID Congress Report Blog Graphic

Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting

Lilly Press Release Graphic

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Also Read

022 SID Congress Report Blog Graphic
congress report

Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting

The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.